Show
Sort by
-
CYAD-01, an autologous NKG2D-based CART-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK) : haematological cohorts of the dose escalation segment of a phase 1 trial
-
- Journal Article
- A1
- open access
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening : an international, multicentre, retrospective cohort study
-
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial